Can ashwagandha cure gynecomastia? It is a question increasingly asked online, but the short answer is no — there is no clinical evidence to support this claim. Gynaecomastia, the benign enlargement of glandular breast tissue in males, has recognised medical causes and established treatment pathways in the UK. While ashwagandha is a popular herbal supplement with some evidence for stress reduction and modest testosterone support, it has not been studied as a treatment for gynaecomastia. This article explains what the evidence actually shows, outlines clinically recognised treatments, and advises when to seek medical assessment.

What Is Gynecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by a relative excess of oestrogen over androgen activity; causes include puberty, medications, medical conditions, and hormone-secreting tumours.

Gynaecomastia is the benign enlargement of glandular breast tissue in males, affecting one or both breasts. It is a relatively common condition, occurring at various life stages — including infancy, adolescence, and older adulthood — and is distinct from pseudogynaecomastia, which refers to fat accumulation in the chest area without true glandular growth. It is worth noting that obesity can contribute to both conditions simultaneously, as excess adipose tissue increases aromatisation of androgens to oestrogens.

The underlying cause is typically an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. When oestrogen effects are relatively elevated compared to androgens, glandular tissue can proliferate. Common causes include:

• Physiological changes during puberty or ageing

• Medications — a wide range of drugs are implicated, including anabolic steroids, anti-androgens (e.g., bicalutamide, finasteride, dutasteride), spironolactone, antipsychotics (e.g., risperidone), antiretrovirals, digoxin, cimetidine, and some antihypertensives

• Medical conditions including hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease, Klinefelter syndrome, and malnutrition or refeeding states

• Hormone-secreting tumours, particularly hCG-secreting testicular tumours, which are an important cause to exclude

• Recreational substances such as cannabis, alcohol, and opioids

• Idiopathic causes, where no clear trigger is identified

In adolescent males, gynaecomastia often resolves spontaneously within one to two years. However, persistent or painful breast enlargement, or cases associated with an underlying medical condition, warrant clinical evaluation.

It is important to distinguish gynaecomastia from male breast cancer, which, although rare, can present similarly. In line with NICE NG12 (Suspected Cancer: Recognition and Referral), men aged 50 or over with a unilateral, hard subareolar mass — with or without nipple changes or discharge — should be referred urgently via the 2-week-wait pathway. Additional red flags requiring prompt assessment include blood-stained nipple discharge, nipple inversion, skin dimpling or peau d'orange, axillary lymphadenopathy, and any rapidly growing or irregular breast lump. Any such features should be assessed by a healthcare professional without delay.

What Is Ashwagandha and How Is It Used in the UK?

Ashwagandha is sold in the UK as an unlicensed food supplement, not a licensed medicine; it carries potential risks including hepatotoxicity and thyroid effects, and should be used with caution.

Ashwagandha (Withania somnifera) is a medicinal herb originating from Ayurvedic medicine, traditionally used in South Asia for centuries as an adaptogen — a substance believed to help the body manage stress and restore physiological balance. Its active constituents include withanolides, alkaloids, and saponins, which are thought to contribute to its reported biological effects.

In the UK, ashwagandha is widely available as a food supplement in capsule, powder, and tincture form, sold in health food shops and online retailers. Most products are sold as food supplements and are not licensed as medicines by the Medicines and Healthcare products Regulatory Agency (MHRA). A small number of herbal products may carry a Traditional Herbal Registration (THR) mark, which indicates that the product meets certain quality and safety standards, but this is not equivalent to a full marketing authorisation and does not confirm clinical efficacy. Consumers should look for the THR mark as a minimum quality indicator when choosing herbal products.

Research has explored ashwagandha's potential effects in several areas, including:

• Stress and anxiety reduction via modulation of the hypothalamic-pituitary-adrenal (HPA) axis

• Testosterone support — some small, short-term randomised controlled trials in men with documented low testosterone have shown modest increases in serum testosterone; however, these studies involved specific populations, used variable product standardisation, and results should not be generalised

• Anti-inflammatory and antioxidant properties

• Improvements in physical performance and muscle recovery

Safety considerations Ashwagandha is not without risk. Rare but serious cases of liver injury (hepatotoxicity) have been reported in association with its use, and the UK Committee on Toxicity (COT) has reviewed this safety signal. If you experience symptoms such as jaundice (yellowing of the skin or eyes), dark urine, pale stools, severe itching, or right-upper-quadrant abdominal pain whilst taking ashwagandha, stop use immediately and seek medical advice.

Ashwagandha may also affect thyroid hormone levels and should be used with caution — or avoided — by people with thyroid disorders. It is not recommended during pregnancy or breastfeeding unless specifically advised by a clinician. People with autoimmune conditions should also seek medical advice before use.

Potential interactions with prescription medicines are possible, particularly with sedatives and CNS depressants, immunosuppressants, thyroid medicines, and anticoagulants. Always consult your GP or pharmacist before taking ashwagandha alongside any prescribed medication.

Suspected adverse reactions to herbal supplements, including ashwagandha, can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Current Evidence on Ashwagandha and Gynecomastia

There is no clinical evidence that ashwagandha treats or cures gynaecomastia; no trials have measured it as an outcome, and it should not replace evidence-based medical assessment.

There is currently no clinical evidence to support the claim that ashwagandha can cure or treat gynaecomastia. No randomised controlled trials, systematic reviews, or NICE-endorsed guidelines recommend ashwagandha as a treatment for this condition. Any suggestion that it can resolve breast tissue enlargement in males is not supported by robust scientific data.

Some proponents argue that because ashwagandha may modestly raise testosterone levels in certain populations — particularly men with documented low testosterone — it could theoretically help restore the androgen-to-oestrogen ratio and thereby reduce gynaecomastia. However, the studies demonstrating any testosterone effect are small, short-term, and conducted in specific populations; they cannot be generalised to men with normal testosterone levels or to the treatment of gynaecomastia. Crucially, none of these trials measured gynaecomastia as an outcome.

A causal link between ashwagandha supplementation and the development of gynaecomastia has not been established in peer-reviewed literature. While some anecdotal accounts exist, these do not constitute reliable evidence of causation. The hormonal effects of ashwagandha are not fully characterised, and it is important not to overinterpret limited or unverified data in either direction.

It is also worth noting that ashwagandha has been associated with rare cases of thyroid dysfunction and liver injury, both of which could potentially confound endocrine symptoms. This further underscores the importance of medical assessment rather than self-treatment with supplements.

In summary, there is no evidence that ashwagandha treats gynaecomastia, and it should not be used as a substitute for evidence-based medical assessment and management. Individuals seeking to address gynaecomastia should consult a qualified healthcare professional rather than relying on unregulated supplements.

Clinically Recognised Treatments for Gynecomastia in the UK

UK management of gynaecomastia focuses on treating the underlying cause, with off-label SERMs such as tamoxifen used in specialist settings and surgery reserved for persistent or fibrotic cases.

The management of gynaecomastia in the UK is guided by clinical assessment of the underlying cause, duration, severity, and impact on the patient's quality of life. NICE and NHS guidance emphasise that treatment should be tailored to the individual, and that many cases — particularly in adolescents — resolve without intervention.

First-line approach: Addressing the underlying cause Where gynaecomastia is linked to a specific medication, recreational drug, or medical condition, addressing that cause is the primary step. Discontinuing or switching a causative drug (under medical supervision) may lead to gradual resolution of breast tissue changes.

Pharmacological options Although no medicines are specifically licensed in the UK for gynaecomastia, some are used off-label in specialist settings and should only be initiated and monitored by a specialist (e.g., endocrinologist or breast surgeon) following a thorough discussion of risks and benefits:

• Tamoxifen (a selective oestrogen receptor modulator, SERM) has shown benefit in reducing breast pain and glandular tissue, particularly in early or active gynaecomastia. It is used off-label in this context.

• Raloxifene is another SERM occasionally used in specialist endocrinology or breast clinics, also off-label.

• These treatments are generally more effective in the early, proliferative phase of the condition — typically within approximately 6 to 12 months of onset — before fibrosis becomes established.

• Aromatase inhibitors and danazol have limited evidence and are not routinely recommended in UK practice.

Surgical management For persistent or longstanding gynaecomastia — particularly where fibrosis has occurred — surgery is often the most effective option. Procedures include subcutaneous mastectomy or liposuction-assisted techniques, typically performed by a plastic or breast surgeon. NHS funding for surgical treatment depends on local Integrated Care Board (ICB) criteria and the degree of psychological or physical impact on the individual.

Psychological support Gynaecomastia can significantly affect body image and mental wellbeing. Referral to psychological support services may be appropriate, particularly for adolescents or those experiencing significant distress.

When to Speak to a GP About Gynaecomastia

You should see a GP if breast enlargement persists beyond two years, is painful, rapidly growing, or associated with nipple or skin changes, as these may require urgent investigation to exclude cancer.

Many men and young people feel embarrassed about gynaecomastia and may delay seeking medical advice, turning instead to supplements or online remedies. However, it is important to consult a GP to rule out underlying medical causes and to access appropriate, evidence-based care.

You should speak to your GP if you notice:

• Breast tissue enlargement that persists beyond two years, particularly in adolescents

• Breast pain, tenderness, or nipple discharge

• A hard, irregular, or rapidly growing lump in one or both breasts

• Nipple inversion, skin dimpling, or peau d'orange changes

• Enlargement that appears to be worsening rather than improving

• Associated symptoms such as fatigue, changes in libido, or unexplained weight changes

• Gynaecomastia that is causing significant psychological distress or affecting daily life

Seek urgent medical attention if you are a man aged 50 or over with a unilateral, hard subareolar mass, or if you notice blood-stained nipple discharge, axillary swelling, or skin changes. In line with NICE NG12, your GP should consider an urgent 2-week-wait referral to a breast clinic to exclude male breast cancer in these circumstances.

Your GP will typically take a thorough medical and medication history, perform a physical examination — including testicular examination — and may arrange blood tests to assess hormone levels (including testosterone, oestradiol, LH, FSH, prolactin, and hCG where clinically indicated), thyroid function, and liver and kidney function. Testicular ultrasound may be requested if examination findings or hormone results suggest the possibility of a testicular tumour. Depending on the suspected cause, referral pathways may include a breast clinic, endocrinology, or urology.

If you are currently taking ashwagandha or any other herbal supplement and have noticed breast changes, please mention this to your GP, as supplements can influence hormone levels and may be relevant to your assessment. Do not start, stop, or change any supplement or medication without professional guidance. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

In summary, while ashwagandha is a widely used supplement with some evidence for general wellbeing benefits, it cannot cure gynaecomastia, and relying on it in place of medical evaluation could delay appropriate diagnosis and treatment. Early assessment by a healthcare professional remains the safest and most effective course of action.

Frequently Asked Questions